Magellan Health Appoints Dr. Caroline Carney as Chief Medical Officer
June 16 2020 - 4:30PM
Business Wire
Magellan Health, Inc. (NASDAQ: MGLN) today announced it has
appointed Caroline Carney, MD, MSc, FAPM, CPHQ, as chief medical
officer of Magellan Health.
In this key leadership role, Dr. Carney will advance Magellan
Health’s clinical mission and further position the company’s
significant leadership capabilities in clinical engagement. She
will also continue to serve as the chief medical officer of
Magellan Rx Management, leading the development and implementation
of innovative, integrated clinical programs for customers and
members of Magellan’s pharmacy business segment.
“The opportunity to address complex, high cost care through
clinical innovation is significant,” said Ken Fasola, chief
executive officer, Magellan Health. “The leadership team and I look
forward to working with Caroline who brings a unique blend of
valuable clinical expertise to Magellan as we bring to life a
differentiated physical and behavioral health experience for the
people we serve.”
“I am so honored to have been chosen for this role at a time
when fully integrating behavioral and physical health remains a
critical societal need,” said Dr. Carney. “I look forward to
engaging with key stakeholders on a whole person approach that will
benefit from Magellan’s deep clinical expertise.”
Dr. Carney, a board-certified internist and a board-certified
psychiatrist, has held key clinical leadership positions serving
complex populations over the span of her career. She joined
Magellan Health in 2016 and currently serves as the chief medical
officer for Magellan Rx Management. She previously held the role of
chief medical officer of Magellan’s Behavioral and Specialty Health
business segments. Before joining Magellan, she was the chief
medical officer for regional health plans focused on Medicaid,
Medicare, Exchange, and commercial populations.
Prior to that, she served as the medical director for the
Indiana Office of Medicaid Policy and Planning, helping to launch
the Medicaid expansion product as well as the behavioral health
transformation for the state’s community mental health services.
Dr. Carney is a published author and co-author for over 100 peer
and non-peer reviewed publications focusing on issues surrounding
comorbid medical and behavioral health conditions.
She earned her medical degree, as well as a master’s degree from
the University of Iowa where she also directed the Med-Psych
residency program. She continues to provide clinical support to a
behavioral health team at a federally qualified health center.
About Magellan Health: Magellan Health, Inc., a Fortune
500 company, is a leader in managing the fastest growing, most
complex areas of health, including special populations, complete
pharmacy benefits and other specialty areas of healthcare. Magellan
supports innovative ways of accessing better health through
technology, while remaining focused on the critical personal
relationships that are necessary to achieve a healthy, vibrant
life. Magellan's customers include health plans and other managed
care organizations, employers, labor unions, various military and
governmental agencies and third-party administrators. For more
information, visit MagellanHealth.com.
Forward-Looking Statements
This press release includes statements which may constitute
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
the accuracy of which are necessarily subject to risks,
uncertainties, and assumptions as to future events that may not
prove to be accurate. These statements are neither promises nor
guarantees, but are subject to a variety of risks and
uncertainties, many of which are beyond our control, which could
cause actual results to differ materially from those contemplated
in these forward-looking statements. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
Factors that could cause actual results to differ materially from
those expressed or implied include the effectiveness of business
continuity plans during the COVID-19 pandemic, the possible
election of certain of the Company’s customers to manage the
healthcare services of their members directly; changes in rates
paid to and/or by the Company by customers and/or providers; higher
utilization of healthcare services by the Company’s members; risks
and uncertainties associated with the pharmacy benefits management
industry; delays, higher costs or inability to implement new
business or other Company initiatives; the impact of changes in the
contracting model for Medicaid contracts; termination or
non-renewal of customer contracts; the impact of new or amended
laws or regulations; governmental inquiries; litigation;
competition; operational issues; healthcare reform; and general
business conditions. Additional factors that could cause actual
results to differ materially from those reflected in the
forward-looking statements include, but are not limited to, the
risks discussed in the “Risk Factors” section included within the
Company’s most recent Annual Report on Form 10-K, quarterly report
on Form 10-Q, and subsequent reports on Forms 10-Q and 8-K. The
Company undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise, except as may be required under
applicable securities law.
(MGLN-GEN)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200616005889/en/
Media Contact: Lilly Ackley,
ackleyl@magellanhealth.com, (860) 507-1923 Investor
Contact: Joe Bogdan, jbogdan@magellanhealth.com,
(860) 507-1910
Magellan Health (NASDAQ:MGLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Magellan Health (NASDAQ:MGLN)
Historical Stock Chart
From Apr 2023 to Apr 2024